CO2024015096A2 - Proceso mejorado para la fabricación de osimertinib - Google Patents

Proceso mejorado para la fabricación de osimertinib

Info

Publication number
CO2024015096A2
CO2024015096A2 CONC2024/0015096A CO2024015096A CO2024015096A2 CO 2024015096 A2 CO2024015096 A2 CO 2024015096A2 CO 2024015096 A CO2024015096 A CO 2024015096A CO 2024015096 A2 CO2024015096 A2 CO 2024015096A2
Authority
CO
Colombia
Prior art keywords
osimertinib
manufacture
improved process
improved
specification relates
Prior art date
Application number
CONC2024/0015096A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Kieron Mullen
Alessandro Pozzoli
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2024015096A2 publication Critical patent/CO2024015096A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CONC2024/0015096A 2022-04-07 2024-11-05 Proceso mejorado para la fabricación de osimertinib CO2024015096A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362622P 2022-04-07 2022-04-07
PCT/EP2023/059132 WO2023194531A1 (en) 2022-04-07 2023-04-06 Improved process for the manufacture of osimertinib

Publications (1)

Publication Number Publication Date
CO2024015096A2 true CO2024015096A2 (es) 2024-11-28

Family

ID=86142780

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0015096A CO2024015096A2 (es) 2022-04-07 2024-11-05 Proceso mejorado para la fabricación de osimertinib

Country Status (14)

Country Link
US (1) US20250250255A1 (https=)
EP (1) EP4504718A1 (https=)
JP (1) JP2025511404A (https=)
KR (1) KR20250002363A (https=)
CN (1) CN119317624A (https=)
AR (1) AR128999A1 (https=)
AU (1) AU2023250220A1 (https=)
CA (1) CA3255378A1 (https=)
CO (1) CO2024015096A2 (https=)
IL (1) IL316018A (https=)
MX (1) MX2024012370A (https=)
TW (1) TW202404955A (https=)
WO (1) WO2023194531A1 (https=)
ZA (1) ZA202408113B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120717920A (zh) * 2025-08-18 2025-09-30 爱斯特（成都）生物制药股份有限公司 一种微通道连续合成3-硝基-4-氟苯腈的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
IN201741031902A (https=) * 2017-09-08 2019-03-15 Msn Laboratories Private Ltd
CN109134435B (zh) 2018-10-29 2023-01-03 湖南大学 一种奥希替尼azd9291的合成方法

Also Published As

Publication number Publication date
JP2025511404A (ja) 2025-04-15
CN119317624A (zh) 2025-01-14
AR128999A1 (es) 2024-07-03
ZA202408113B (en) 2025-07-30
KR20250002363A (ko) 2025-01-07
TW202404955A (zh) 2024-02-01
WO2023194531A1 (en) 2023-10-12
MX2024012370A (es) 2024-11-08
AU2023250220A1 (en) 2024-11-07
IL316018A (en) 2024-11-01
EP4504718A1 (en) 2025-02-12
CA3255378A1 (en) 2023-10-12
US20250250255A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
UY39831A (es) Métodos para reducir la producción de metano
CO2021017845A2 (es) Proteínas multiespecíficas
CL2023002610S1 (es) Porción de un reloj inteligente.
CL2023001049A1 (es) Procedimiento para la fabricación de compuestos orgánicos
CO2024015096A2 (es) Proceso mejorado para la fabricación de osimertinib
CL2022001404A1 (es) Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa
CL2024003023A1 (es) Inhibidores lrrk2.
MX2021012754A (es) Proceso para la produccion de acido metanosulfonico anhidro a partir de metano y so3.
MX2020011051A (es) Conversion mejorada de taurina a amida de alquiltaurato utilizando catalizadores de acido fosforico.
CO2022011862A2 (es) Proceso para la preparacion de compuestos de antranilamida artropodicida
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
CL2023001137A1 (es) Procedimiento para la purificación de pleuromutilinas
AR125115A1 (es) PROCEDIMIENTO PARA LA DETERMINACIÓN CUANTITATIVA DE Al₄C₃, ASÍ COMO DISPOSITIVO PARA LA REALIZACIÓN DEL PROCEDIMIENTO
CL2023001760A1 (es) Proceso
MX2023008364A (es) Metodo para el tratamiento de enfermedades renales cronicas.
AR120518A1 (es) Método para fabricar una partícula
MX2021016001A (es) Proceso para fabricar 3,5-difluoro-benzilamida de acido (s)-3-hidroxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxilico.
MX2022006178A (es) Composiciones que comprenden tricianohexano.
CL2024002665A1 (es) Proceso para la preparación de compuestos de 1,1-dialcoxi-alquinol.
CL2024000493A1 (es) Método para la obtención de fibras solubles enzimáticamente
JP1740342S (ja) 靴
MX2022004064A (es) Proceso para elaborar acidos alcansulfonicos.
MX2024005029A (es) Un método para producir tequila
MX2023007906A (es) Proceso para preparar el dialdehido de vinilciclohexeno.
CL2025002806S1 (es) Periferia de la entresuela de un calzado.